No Data
No Data
Institutional Owners May Ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) Recent US$92m Market Cap Decline as Longer-term Profits Stay in the Green
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $40
TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
Express News | HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target
Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib
Express News | Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib
104016428 : will that mean that after their presentation on June 1 it might fly high on monday? or when the news is out for ASCO that's the end of the rally